Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Dual-Trained Rheumatologists Take Multidisciplinary Approach to Their Patients

Gretchen Henkel  |  Issue: October 2015  |  October 14, 2015

Dr. Dellaripa and Dr. Goldberg (seated), co-directors of the Interstitial Lung Disease Clinic, with additional staff members.

Dr. Dellaripa and Dr. Goldberg (seated), co-directors of the Interstitial Lung Disease Clinic, with additional staff members.

Co-morbidities in patients with rheumatoid arthritis and related autoimmune diseases often warrant a multidisciplinary approach to treatment. When it comes to inflammatory and fibrotic lung conditions in these patients, collaboration between pulmonary/critical care specialists and rheumatologists is essential, say two rheumatologists recently interviewed by The Rheumatologist. Both followed their rheumatology fellowship training with additional fellowships in critical care medicine. Their reasons for combining the two specialties are particular to each physician, although they both share the drive to improve their patients’ complicated co-disorders.

Capacity to Influence & Guide Care

“If you look at some of the data for lung diseases associated with the rheumatic diseases, the mortality associated with these patients approaches some types of cancer,” notes Paul F. Dellaripa, MD, co-director of the Interstitial Lung Disease Clinic and associate professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, Boston. “The five-year mortality for lung disorders, such as RA or dermatomyositis, is quite high,” says Dr. Dellaripa.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Dellaripa’s choice to follow his rheumatology fellowship at Tufts University School of Medicine with one in critical care at the Lahey Clinic and Beth Israel Deaconess Medical Center arose from an initial frustration over how his rheumatology patients admitted to the ICU were handled. He had always enjoyed critical care medicine and began to contemplate pursuing an additional fellowship in that discipline. To be sure that it would be a viable career path, he took a year off and worked with another physician in critical care in a community ICU. He reports that although his mentors did not have much direct experience with combining both specialties—and there had not been anyone else pursuing both—“they encouraged me to build a new bridge between two disciplines.”

Dr. Dellaripa then practiced as a rheumatologist and critical care specialist for 11 years at Lahey Clinic, a physician-led nonprofit teaching hospital of Tufts University in Burlington, Mass. “As time went on, I began to see more and more patients whose pulmonary disorders were related primarily to their rheumatologic disease,” he recalls.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When his rheumatology patients became critically ill, he notes that many pulmonary/critical care physicians seemed uncomfortable with, or even unaware of, the unique pulmonary problems his patients presented. That’s when his interests began to shift, he says. He decided to refocus his critical care training, “which had a pulmonary bent,” and moved to Brigham and Women’s to open a lung disease clinic. Combining rheumatology with pulmonary critical care, he reasoned, “would give me the capacity to influence and guide both inpatient and outpatient care.”

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Career DevelopmentConditionsProfessional TopicsRheumatoid Arthritis Tagged with:ClinicalDiagnosislung disorderpatient careRARheumatoid arthritisrheumatologistrhuematologyTreatment

Related Articles

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    New Africa / shutterstock.com

    A Rheumatologist & Pulmonologist Discuss RA-ILD

    November 14, 2021

    Introduction The understanding and treatment of rheuma­toid arthritis (RA) has evolved dramatically in the past 20 years. As gains have been made in treating joint disease in RA, our understanding of the impact of extra-articular manifestations of RA, such as cardiac and lung disease—specifically interstitial lung disease (ILD)—has gradually increased. While rheumatologists increasingly appreciate the…

    Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

    September 22, 2021

    Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences